Glaucoma Clinical Trial
Official title:
Follow-up of the First in Man, Prospective, Open-label, Single Arm, Multicenter Clinical Investigation to Assess the Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery (Follow-up Month 12 - Month 36)
Verified date | March 2022 |
Source | Implandata Ophthalmic Products GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.
Status | Active, not recruiting |
Enrollment | 21 |
Est. completion date | February 20, 2023 |
Est. primary completion date | February 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects of the ARGOS-SC01 study with an implanted ARGOS-SC suprachoroidal pressure sensor. Exclusion Criteria: - N/A |
Country | Name | City | State |
---|---|---|---|
Germany | Universitäts-Augenklinik Bochum | Bochum | |
Germany | Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik | Mainz | |
Germany | Augenklinik der LMU München | München | |
Germany | Knappschaftsklinikum Saar GmbH, Augenklinik Sulzbach | Sulzbach | |
Switzerland | Swiss Glaucoma Research Foundation, Centre du Glaucome, Clinique Montchoisi | Lausanne |
Lead Sponsor | Collaborator |
---|---|
Implandata Ophthalmic Products GmbH | CRO Dr. med. Kottmann GmbH & Co. KG |
Germany, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance | Level of Agreement between measurements made using GAT, Pascal DCT and the ARGOS-SC system from V09 (month 12) through V13 (month 36). | Day 360 to Day 1080 | |
Secondary | Safety: Number of patients experiencing a device-related SAE (SADE) | Number of patients experiencing a device-related SAE (SADE) | Day 360 to Day 1080 | |
Secondary | Safety: Incidence of observed adverse events | Incidence of observed adverse events | Day 360 to Day 1080 | |
Secondary | Safety: Nature of observed adverse events | Nature of observed adverse events | Day 360 to Day 1080 | |
Secondary | Safety: Severity of observed adverse events | Severity of observed adverse events | Day 360 to Day 1080 | |
Secondary | Safety: Seriousness of observed adverse events | Seriousness of observed adverse events | Day 360 to Day 1080 | |
Secondary | Safety: Incidence of adverse device events | Incidence of adverse device events | Day 360 to Day 1080 | |
Secondary | Safety: Nature of adverse device events | Nature of adverse device events | Day 360 to Day 1080 | |
Secondary | Safety: Severity of adverse device events | Severity of adverse device events | Day 360 to Day 1080 | |
Secondary | Safety: Seriousness of adverse device events | Seriousness of adverse device events | Day 360 to Day 1080 | |
Secondary | Performance | Repeatability of the ARGOS-SC measurement (IOP Measurement compared to GAT in mmHg) | Day 360 to Day 1080 | |
Secondary | Performance | Incidence of observed device malfunctions | Day 360 to Day 1080 | |
Secondary | Performance | Nature of observed device malfunctions | Day 360 to Day 1080 | |
Secondary | Performance | Seriousness of observed device malfunctions | Day 360 to Day 1080 | |
Secondary | Utility | User acceptance of the ARGOS-SC system at the investigational site by means of evaluation of physician acceptance questionnaires (by investigators) | Day 360, Day 1080 | |
Secondary | Utility | User acceptance of the ARGOS-SC system at home by means of evaluation of patient acceptance questionnaires (patients) | Day 360, Day 1080 | |
Secondary | Utility | Daily IOP self-measurement profiles (patients) | Day 360 to Day 1080 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |